Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

ICON Announces Release of ADDPLAN® neo


Software provides an integrated technology platform for adaptive
clinical trials

(NASDAQ:ICLR) a global provider of drug development services to
the pharmaceutical, biotechnology and medical device industries, today
announced the release of ADDPLAN® neo, providing an advanced validated
integrated technology platform for design, simulation and analysis of
adaptive clinical trials.

The new release combines ADDPLAN® BASE, ADDPLAN® MC (for Multiple
Comparison Designs) and ADDPLAN® DF (for dose ranging and dose finding
trials using MCP-Mod methodology) modules under one umbrella, increasing
simulation speed for each application and allowing computation of
multiple projects on one, integrated robust framework. The software has
been rewritten using C programming language to ensure efficient usage of
computing resources and fast simulation results.

Following feedback from customers, ICON enhanced the algorithms'
stability and speed and added new features such as the ability to
incorporate custom R code in the ADDPLAN® neo Dose Finding module.

Additional ADDPLAN® neo features include:

  • Every-Phase Capabilities – Strengthen and advance study design,
    simulation and analysis for every phase of drug development, including
    Adaptive MCP-Mod, critical for dose-finding designs.
  • Improved User Experience – A fully validated, graphical user interface
    (GUI) software, ADDPLAN® neo features a quick access to adaptive
    approaches across all phases of drug development.

Andrew Garrett, EVP Scientific Operations said "With the recent FDA
announcement of its Complex Innovative Designs Pilot Meeting Program,
targeted at innovative trial designs to inform regulatory decision
making, the door is very much open for adaptive and other types of
innovative design. ADDPLAN
® neo provides an integrated and
increasingly flexible solution that truly supports this innovation
agenda by providing a validated tool that helps convert theory to

About ICON plc
ICON plc is a global provider of outsourced
drug development and commercialisation solutions and services to
pharmaceutical, biotechnology, medical device, and government and public
health organisations. The company specializes in the strategic
development, management and analysis of programs that support clinical
development from compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 93
locations in 37 countries and has approximately 13,675 employees.

Further information is available at


This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at

View Comments and Join the Discussion!